Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTION: Organ Preservation With Active Surveillance After Chemoradiation in Rectal Cancer
NCT03594630Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial in rectal cancer (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall organ preservation rate at 12 months, Local tumor regrowth rate at 12 months and 1 more. Started Mar 2024; status: recruiting.
02
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03594630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594630.